The Avanzar study could read out shortly.
ApexOnco Front Page
Recent articles
Satri-cel is filed for gastric cancer approval in China.
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
The company reports an “unprecedented” 100% PSA50 rate with JANX007, but in a small, selected number of patients.
